Analyst firms · UBS · PODD

UBS PODD price target and rating history

Insulet Corporation (PODD) · Health Care

UBS rates Insulet Corporation (PODD) Neutral with a $174 price target, as of its latest action on Jul 28, 2026. It has published 3 rating actions on PODD since February 2022, including 2 upgrades and 0 downgrades. Across 10 firms with a PODD price target in the last 12 months, the median target is $182. UBS's $174 is 4% below that.

Current rating

Neutral

Price target

$174

Median target, all firms

$182

Actions on PODD

3

UBS price target on PODD

Every UBS rating on PODD

• Jul 28, 2026
  ResumeUBS resumes coverage at Neutral, price target $174
• Nov 19, 2025
  UpgradeUBS upgrades to Buy from Neutral, price target $400
• Feb 2, 2022
  UpgradeUBS upgrades to Buy from Neutral, price target $325

How other firms rate PODD

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and PODD

What is UBS's price target for PODD?

UBS's latest stated price target for Insulet Corporation (PODD) is $174, from its action on Jul 28, 2026.

What is UBS's rating on PODD?

UBS rates PODD Neutral, a neutral rating, as of Jul 28, 2026.

When did UBS last change its view on PODD?

On Jul 28, 2026, UBS resumes coverage at Neutral, price target $174.

How does UBS's PODD target compare with other analysts?

Across 10 firms with a PODD price target in the last 12 months, the median target is $182. UBS's $174 is 4% below that.

More PODD rating histories

• Barclays3
• Leerink Partners4
• Oppenheimer3
• Citigroup3
• Wolfe Research4
• Morgan Stanley5

All UBS ratingsPODD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.